NICE publishes latest drug decisions

The National Institute of Clinical Excellence (NICE) has issued its latest decisions on the use of drugs on the NHS in England and Wales.

The agency has accepted denosumab for restricted use in the prevention of osteoporotic fragility fractures in postmenopausal women. Liraglutide, at a daily dose of 1.2mg, is accepted for restricted use in dual and triple therapy of patients with type 2 diabetes.

NICE was unable to recommend bendamustine for the treatment of indolent rituximab-resistant non-Hodgkin’s lymphoma because no supporting evidence was submitted. For the same reason, temsirolimus could not be recommended for the treatment of relapsed or refractory mantle cell lymphoma.

The agency also rejected ofatumumab for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab; omalizumab for severe persistent allergic asthma in children aged 6 to 11 years; and eltrombopag for chronic immune (idiopathic) thrombocytopenic purpura.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Compare COVID-19 vaccines with new MIMS table

Compare COVID-19 vaccines with new MIMS table

Key characteristics of available COVID-19 vaccines...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...